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Over the last three decades industrial adaptability has allowed hot-melt extrusion (HME) to gain wide acceptance and has already
established its place in the broad spectrum of manufacturing operations and pharmaceutical research developments. HME has
already been demonstrated as a robust, novel technique to make solid dispersions in order to provide time controlled, modified,
extended, and targeted drug delivery resulting in improved bioavailability as well as taste masking of bitter active pharmaceutical
ingredients (APIs). This paper reviews the innumerable benefits of HME, based on a holistic perspective of the equipment,
processing technologies to the materials, novel formulation design and developments, and its varied applications in oral drug
delivery systems.
1. Introduction
To date HME has emerged as a novel processing technology
in developing molecular dispersions of active pharmaceu-
tical ingredients (APIs) into various polymer or/and lipid
matrices which has led this technique to demonstrate time
controlled, modified, extended, and targeted drug delivery
[1–4]. HME has now provided opportunity for use of mate-
rials in order to mask the bitter taste of active substances.
Since the industrial application of the extrusion process
back in the 1930’s, HME has received considerable attention
from both the pharmaceutical industry and academia in a
range of applications for pharmaceutical dosage forms, such
as tablets, capsules, films, and implants for drug delivery
via oral, transdermal, and transmucosal routes [5]. This
makes HME an excellent alternative to other conventionally
available techniques such as roll spinning and spray drying.
In addition to being a proven manufacturing process, HME
meets the goal of the US Food and Drug Administration’s
(FDA) process analytical technology (PAT) scheme for
designing, analyzing, and controlling the manufacturing
process via quality control measurements during active
extrusion process [6]. In this chapter, the hot-melt extrusion
technique is reviewed based on a holistic perspective of
its various components, processing technologies, and the
materials and novel formulation design and developments in
its varied applications in oral drug delivery systems.
2. Process Technology of Hot-Melt
Extrusion (HME)
Hot-melt extrusion technique was first invented for the
manufacturing of lead pipes at the end of the eighteenth
century [7]. Since then, it has been used in the plastic, rubber,
and food manufacturing industry to produce items ranging
from pipes to sheets and bags. With the advent of high
throughput screening, currently more than half of all plastic
products including bags, sheets, and pipes are manufactured
my HME and therefore various polymers have been used to
melt and form diﬀerent shapes for a variety of industrial and
domestic applications. The technology (HME) has proven to
be a robust method of producing numerous drug delivery
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systems and therefore it has been found to be useful in the
pharmaceutical industry as well [8]. Extrusion is the process
of pumping raw materials at elevated controlled temperature
and pressure through a heated barrel into a product of
uniform shape and density [9]. Breitenbach first introduced
the development of melt extrusion process in pharmaceutical
manufacturing operations [10]; however, Follonier and his
coworkers first examined the hot-melt technology to man-
ufacture sustained release polymer-based pellets of various
freely soluble drugs [11]. HME involves the compaction
and conversion of blends from a powder or a granular mix
into a product of uniform shape [9]. During this process,
polymers are melted and formed into products of diﬀerent
shapes and sizes such as plastic bags, sheets, and pipes
by forcing polymeric components and active substances
including any additives or plasticisers through an orifice or
die under controlled temperature, pressure, feeding rate, and
screw speed [9, 12]. However, the theoretical approach to
understanding the melt extrusion process (Figure 1) can be
summarized by classifying the whole procedure of HME
compaction into the following [13]:
(1) feeding of the extruder through a hopper,
(2) mixing, grinding, reducing the particle size, venting,
and kneading,
(3) flow through the die, and
(4) extrusion from the die and further downstream proc-
essing.
The extruder generally consists of one or two rotating
screws (either corotating or counter rotating) inside a sta-
tionary cylindrical barrel. The barrel is often manufactured
in sections in order to shorten the residence time of molten
materials. The sectioned parts of the barrel are then bolted or
clamped together. An end-plate die is connected to the end of
the barrel which is determined according to the shape of the
extruded materials.
3. Single-Screw and Twin-Screw Extruder
A single-screw extruder consists of one rotating screw
positioned inside a stationary barrel at the most fundamental
level. In the more advanced twin-screw systems, extrusion
of materials is performed by either a corotating or counter-
rotating screw configuration [9]. Irrespective of type and
complexity of the function and process, the extruder must
be capable of rotating the screw at a selected predetermined
speed while compensating for the torque and shear generated
from both the material being extruded and the screws being
used. However, regardless of the size and type of the screw
inside the stationary barrel a typical extrusion set up consists
of a motor which acts as a drive unit, an extrusion barrel, a
rotating screw, and an extrusion die [13]. A central electronic
control unit is connected to the extrusion unit in order to
control the process parameters such as screw speed, temper-
ature, and therefore pressure [14]. This electronic control
unit acts as a monitoring device as well. The typical length
diameter ratios (L/D) of screws positioned inside the station-
ary barrel are another important characteristic to consider
whether the extrusion equipment is a single-screw or twin-
screw extruder. The L/D of the screw either in a single-screw
extruder or a twin-screw extruder typically ranges from 20 to
40 : 1 (mm). In case of the application of pilot plant extruders
the diameters of the screws significantly ranges from 18 to
30mm. In pharmaceutical scale up, the productionmachines
are much larger with diameters typically exceeding 50–
60mm [15]. In addition, the dimensions of a screw change
over the length of the barrel. In themost advanced processing
equipment for extrusion, the screws could be separated by
clamps or be extended in proportion to the length of the
barrel itself. A basic single-screw extruder consists of three
discrete zones: feed zone, compression, and a metering zone
(Figure 2). Under the compression zone which is basically
known as processing zone could be accompanied by few
other steps such as mixing, kneading, and venting [13, 15].
The depth along with the pitch of the screw flights (both
perpendicular and axial) diﬀer within each zone, generating
dissimilar pressures along the screw length (Figure 3). Nor-
mally the pressure within the feed zone is very low in order to
allow for consistent feeding from the hopper and gentle mix-
ing of API, polymers, and other excipients and therefore the
screw flight depth and pitch are kept larger than that of other
zones. At this stage of the process the pressure within the
extruder is very low which subsequently gets increased in the
compression zone. This process results in a gradual increase
in pressure along the length of the compression zone, which
eﬀectively imparts a high degree of mixing and compression
to the material (by decreasing the screw pitch and/or the
flight depth) [9, 15]. Moreover the major aim of the com-
pression zone is not only to homogenize but also compress
the extrudate to ensure the molten material reaches the final
section of the barrel (metering zone) in a form appropriate
for processing. Finally the final section which is known as the
metering zone stabilizes the eﬀervescent flow of the matrix
and ensures the extruded product has a uniform thickness,
shape, and size. A constant and steady uniform screw flight
depth and pitch helps to maintain continuous high pressure
ensuring a uniform delivery rate of extrudates through the
extrusion die and hence a uniform extruded product.
In addition to the above-mentioned systems, down-
stream auxiliary equipment for cooling, cutting, and collect-
ing the finished product is also typically employed. Mass flow
feeders to accurately meter materials into the feed hopper,
pelletizers, spheronizer, roller/calendaring device in order to
produce continuous films, and process analytical technology
such as near infrared (NIR) and Raman, ultrasound, and
DSC systems are also options. Throughout the whole
process, the temperature in all zones is normally controlled
by electrical heating bands andmonitored by thermocouples.
The single-screw extrusion system is simple and oﬀers
lots of advantages but still does not acquire the mixing capa-
bility of a twin-screw machine and therefore is not the pre-
ferred approach for the production of most pharmaceutical
formulations. Moreover, a twin-screw extruder oﬀers much
greater versatility (process manipulation and optimisation)
in accommodating a wider range of pharmaceutical for-
mulations making this setup much more constructive. The
rotation of the screws inside the extruder barrel may either
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Figure 2: Schematic diagram of a single-screw extruder [10].
be corotating (same direction) or counter-rotating (opposite
direction), both directions being equivalent from a process-
ing perspective (Figure 4). A greater degree of conveying and
much shorter residence times are achievable with an inter-
meshing setup. Furthermore, the use of reverse-conveying
and forward-conveying elements, kneading blocks, and other
intricate designs as a means of improving or controlling the
level of mixing required can help the configuration of the
screws themselves to be varied [16].
4. Advantages and Disadvantages of HME
HME oﬀers several advantages over conventionally avail-
able pharmaceutical processing techniques including (a)
increased solubility and bioavailability of water insoluble
compounds; (b) solvent-free nonambient process; (c) eco-
nomical process with reduced production time, fewer pro-
cessing steps, and a continuous operation; (d) capabilities of
sustained, modified, and targeted release; (e) better content
uniformity in extrudates; (f) no requirements for the com-
pressibility of active ingredients; (g) uniform dispersion of
fine particles; (h) good stability at changing pH andmoisture
levels and safe application in humans; (i) reduced number of
unit operations and production of a wide range of perfor-
mance dosage forms (j) a range of screw geometries [17–21].
However, HME has some disadvantages as well. Themain
drawbacks of HME include thermal process (drug/polymer
stability), use of a limited number of polymers, high flow
properties of polymers, and excipients required and not
suitable for relatively high heat sensitive molecules such as
microbial species and proteins [20, 21].
5. Overall Applications of HME
Extrusion technology is one of the most important fab-
rication processes in the plastic and rubber industries.
Products made from melt extruded polymers range from
pipes to hoses through to the insulated wires, cables, rubber
sheeting, and polystyrene tiles. Plastics that are commonly
processed by HME technique include acrylics and cellulosics,
polyethylene, poly propylene, polystyrene, and vinyl plastics
[9, 22]. In the food industry, extrusion has been utilized for
pasta production with a widely used multitalented technique
combining cooking and extrusion in a self-styled extrusion
cooker [23]. In the animal feed industry and veterinary
science, extrusion is commonly applied as a means of
producing pelletized feeds, implants, or injection moulding
[24]. HME has successfully been applied in the formulation
of fast dispersing PVP melt extrudates of poorly soluble
active agents as solid molecular dispersions in the crop
protection field [25].
HME technology has already achieved a strong place in
the pharmaceutical industry and academia due to several
advantages over traditional processing methods such as roll
spinning and grinding [18]. In addition to being an eﬃcient
manufacturing process, HME enhances the quality and
eﬃcacy of manufactured products and therefore over the
past few years HME has emerged as a novel technique in
pharmaceutical applications [15, 26]. The main use of HME
is to disperse active pharmaceutical ingredients (APIs) in a
matrix at the molecular level, thus forming solid solutions
[27]. In the pharmaceutical industry, HME has been used for
various applications, such as (i) enhancing the dissolution
rate and bioavailability of poorly soluble drugs by forming
a solid dispersion or solid solution, (ii) controlling or
modifying the release of the drug, (iii) taste masking of bitter
APIs, and (iv) formulation of various thin films [28].
The bioavailability of an active ingredient is controlled by
its aqueous solubility. Therefore, increasing the solubility of
water insoluble drugs is still a real challenge in the formu-
lation development process [27]. Due to the advent of high
throughput screening (HTS) in the drug discovery process,
the resultant compounds are often high molecular weight
and highly lipophilic and therefore exhibit poor solubility
[29]. Scientists have already tried to address solubility issues
by various pharmaceutical interventions. Among the many
methods available to improve solubility and dissolution
rate, preparation of solid dispersions and solid solutions
has gained vast attention. For that reason, HME has been
successfully applied to prepare solid molecular dispersion of
APIs into diﬀerent hydrophilic polymer matrices [27, 29].
6. Applications of HME in
Pharmaceutical Research
Despite the fact that initial research developments have
focused on the eﬀects of formulation and processing vari-
ables on the properties of the final dosage forms, [9, 30–33]
more recent investigations have focused on the use of HME
as a novel manufacturing technology of solid molecular
dispersions through the development of minimatrices, taste
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Figure 4: A twin-screw extruder and screws [9].
masked formulations, and also sustained release formula-
tions as well as paediatric formulations [27, 34]. Early work
by De Brabander et al. (2000) described the preparation of
matrix minitablets which was followed by further investiga-
tions into the properties of sustained release minimatrices
manufactured from ethyl cellulose, HPMC, and ibuprofen
[35, 36]. Extruded minitablets showed minimised risk of
dose dumping, reduced inter- and intrasubject variability.
Very recently, Roblegg et al. reported the development of
retarded release pellets using vegetable calcium stearate
(CaSt) as a thermoplastic excipient processed through HME,
where pellets with a drug loading of 20% paracetamol
released only 11.54% of the drug after 8 hours due to
the significant densification of the pellets. As expected, the
drug release was influenced by the pellet size and the drug
loading [37]. A microbicide intravaginal ring (IVRs) IVR
was prepared and developed from polyether urethane (PU)
elastomers for the sustained delivery of UC781 (a highly
potent nonnucleoside reverse transcriptase inhibitor of HIV-
1). PU IVRs containing UC781 were fabricated using a hot-
melt extrusion process [38].
Moreover, a fourfold increase in the availability of
propanolol in the systemic circulation was observed when the
HME formulation was compared with a commercially avail-
able formulation (Inderal). Over the last five years HME has
been used largely to manufacture granules, pellets, immedi-
ate and modified release tablets, transmucosal/transdermal
films, and implantable reservoir devices [3, 4, 9, 33].
For instance, with respect to drug administration through
the oral route, molecular solid dispersions of nifedipine
[39], nimodipine [29], and itraconazole [40–42] have been
successfully produced using HME technology. Amorphous
indomethacin dispersions have been manufactured using
pharmaceutically acceptable hydrophilic polymers by using
HME technology [27, 43, 44].
Furthermore, HME research developments have driven
targeted drug delivery systems including enteric matrix
tablets and capsule systems over the last few years [45, 46].
Miller et al. have demonstrated the ability of HME to
act as an eﬃcient dispersive process for aggregated, fine
engineering particles to improve dissolution rate properties
by enhancing particles’ wettability [47]. A very inter-
esting investigation of Verreck and coworkers (2006) [48]
determined the use of supercritical carbon dioxide (scCO2)
as a temporary plasticiser during the manufacture of eth-
ylcellulose through HME. A significant reduction in the
processing temperature was achieved using scCO2 without
any disadvantageous eﬀects on the extrudate. Macroscopic
morphology was significantly altered due to expansion
of the scCO2 in the die. The use of scCO2 increased the
surface area, porosity, and hygroscopicity of the final dosage
forms. More recently Douroumis and coworkers used HME
technique to eﬀectively enhance the solubility of ibuprofen,
indomethacin, and famotidine [27, 43].
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The taste masking of bitter APIs is a major challenge
especially for the development of orally disintegrating tablets
(ODT). HME has been reported to be an eﬀective technique
to mask the bitter tastes of various APIs by the use of taste
masking polymers that create solid dispersions to prevent
bitter drugs from coming in contact with the patient’s taste
buds. More recently ibuprofen- and paracetamol-based taste
masked formulations by HME have been reported [1, 43].
In these studies, taste masking has been achieved through
intermolecular forces (e.g., hydrogen bonding) between the
active substance and the polymer matrix by processing
oppositely charged compounds through HME [49, 50].
Gryczke et al. [43] processed up to 40% IBU with only
EPO (50%) and talc (10%) and demonstrated suﬃcient taste
masking during the extrusion. It was found that increasing
IBU concentrations enhanced drug-polymer interactions as
IBU has been found to present plasticising eﬀects compared
to traditional plasticizers. The presence of a single Tg and
the absence of IBU’ melting endotherm confirmed the
complete miscibility of IBU/EPO and the creation of a
glassy solution where IBU was molecularly dispersed within
EPO thus facilitating the higher dissolution rate and better
taste masking eﬃciency. Later on the ground extruded
materials were compressed in tablets and compared with
commercially available Nurofen Meltlets Lemon ODTs and
extruded tablets were found showing better taste masking
eﬃciency as well as about 5-fold increased dissolution of
poorly soluble IBU compared to that of Nurofen. More
recently Maniruzzaman et al. [1] conducted a comparative
taste masking study of extruded paracetamol (PMOL) with
Eudragit EPO and cross-linked polyvinylpyrrolidone (Kolli-
don VA64) at diﬀerent drug loadings ranging (30–60%). The
taste evaluation of the developed formulations carried out by
using an Astree e-tongue equipped with seven sensors and
the generated data were analysed using multidimensional
statistics. The data analysis showed significant suppression of
the bitter taste for PMOL for both polymers.
Actually in the forgoing study taste masking of bitter
PMOL was strongly dependant on the nature of the poly-
meric carriers and the drug loading in the final formulation.
Both polymers showed excellent taste masking for active
concentrations up to 50%. Additionally, in vitro taste analysis
(taste maps) showed significant discrimination between
placebo and extruded formulations (Figure 5).
The extrusion of solid lipids using twin-screw extruders
was introduced for the preparation of immediate or sus-
tained release taste-masked matrices [51]. Being divert from
the polymeric extrusion the lipidic matrices oﬀer several
advantages over polymeric matrices during the extrusion
process. Lipid excipients can easily be processed in 20–
25◦C above the room temperature and sometimes 10–15◦C
lower than the melting temperatures of the lipid itself;
thus, extrusion does not need to be plasticizer assisted or
dependent. Breitkreutz et al. successfully applied HME in
taste masking of sodium benzoate for the formulation of
paediatric drugs [34]. In this study the authors introduced
“cold solvent-free extrusion” which utilizes diﬀerent lipids
in lower temperatures or even slightly above the room
temperatures. In this study sodium benzoate was extruded
with Precirol ATO5 (glycerol distearate), hard fat, and stearic
acid in order to mask the taste of API. Mainly, the eﬀective
taste masking was achieved for at least 5min in the buccal
cavity due to the Eudragit E coating layer which prevented
the release of sodium benzoate. Later on the same group
processed various binary, ternary, and quaternary mixtures
of powdered lipids with sodium benzoate through solvent-
free cold extrusion to prepare immediate release pellets with
solid lipid binders and compare them to well-known wet
extrusion binders such as microcrystalline cellulose or κ-
carrageenan. In this particular study the authors did not
examine the masking eﬃciency of the manufactured lipid
formulations which eventually made cold extrusion process
questionable for the taste masking purposes. However,
further evaluation of this process is a prerequisite until a
considerable optimization is achieved for this method to be
a viable taste masking approach. In these few studies, the
eﬀect of lipid composition and processing parameters such
as the die diameter, the size of the extruded pellets, the screw
speed, and the powder feeding rates on the obtained drug
release patterns were thoroughly investigated. Very recently,
Vaassena et al. (2012) applied solid lipid extrusion at room
temperature for the taste-masked formulation development
of the BCS Class II drug NXP 1210. In this study, the authors
investigated powdered hard fat (Witocan 42/44 mikrofein),
glycerol distearate (Precirol ato 5), and glycerol trimyristate
(Dynasan 114) as lipid binders. The lipid-based formulations
designed in this study was feasible for taste-masked granules
or pellets containing poorly soluble drugs [52].
6.1. Application of HME for the Developments of Films.
However, only a handful of researchers have reported the
use of hot-melt extrusion for the manufacture of films.
Films can be defined as thin sheets containing one or more
polymers with or without a plasticiser and may be used
as a drug delivery system (device) or directly applied to
facilitate a therapeutic eﬀect as in wound dressings. Films are
currently being produced mainly by solvent casting in which
polymers (and excipients such as plasticisers) are dissolved in
a suitable solvent until they form clear viscous solution (gel).
While film preparation using the solvent-casting approach
allows film uniformity, clarity, flexibility, and adjustable
thickness to accommodate drug loadings they are limited
by decreased elongation or elasticity and increased film
tensile strength when physical aging is applied [53]. Another
limitation associated with solvent cast films is the use of
organic solvents for water insoluble polymers. The hazardous
nature of most organic solvents and the residual solvents
after drying aﬀect the selection of the appropriate solvent
[54–57] as well as complicated processing conditions and
disposal of the associated waste, all of which create significant
environmental concerns. As a result, alternative technologies
are needed in the pharmaceutical industry to overcome some
of the challenges described above. The two commonly used
approaches include spray coating and hot-melt extrusion
with the latter becoming increasingly popular due to the
many advantages it provides. Firstly, no solvents are used and
fewer processing steps are required. In fact one of the key
advantages of HME is the fact that extrudates can be obtained
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polymer after dissolution for 60 s [1].
in a single processing step making it very economical. As
far as films are concerned, there is no requirement for
compressing of the active ingredients together with the
excipients. The melting of the polymer into the molten
state, coupled with the thorough initial mixing, allows a
more uniform dispersion of fine particles. Further, molecular
dispersion of the drug helps to improve its bioavailability
[58]. Hot-melt extruded films are produced through a
simple process involving blending of appropriate amounts
of relevant polymer, drug, and plasticiser into a uniform
powderedmixture prior to feeding through the hopper of the
preheated extruder and transferred into the heated barrel by
a rotating extruder screw. Homogeneous films are obtained
with thickness generally expected to be in the range less
than 1mm. Generally three main ingredients are required
for successful formulation of hot-melt films, that is, film
forming polymer, active ingredient, and plasticiser [59].
The latter is required to impart flexibility to the final film
which ensures ease of handling and application to the site
of action. Occasionally, other additives are added to aﬀect
other functionally important properties such as bioadhesive
agent which ensures that the film adheres to the mucosal
surface for a long enough time to allow drug absorption or
action. Diﬀerent polymers and drugs have been employed
and reported in the literature for obtaining drug-loaded
hot-melt extruded films for various indications and are
summarised in Table 1.
Repka and coworkers have conducted extensive research
on the use of HME for the manufacture of mucoadhesive
buccal films. They successfully evaluated diﬀerent matrix
formers and additives for the processing of the blend prior
to extrusion [60–63]. In an early investigation, it was found
that even though films containing exclusively HPC could
not be obtained, the addition of plasticizers, such as triethyl
citrate, PEG 2000/8000, or acetyltributyl citrate, allowed for
the manufacture of thin, flexible, and stable HPC films [64].
It has also been found that increasing themolecular weight of
HPC decreased the release of drugs from hot-melt-extruded
films which resulted in dissolution profiles exhibiting zero-
order drug release. According to the models applied in the
research, the drug release was solely determined by erosion
of the buccal film [65–67].
Development of films by HME may present future
opportunities to develop gastroretentive films for prolonged
drug delivery and multilayer films to modulate drug release
for oral and transdermal applications. The growingmarket in
medical devices, including incorporating drugs into devices
such as biodegradable stents and drug-loaded catheters, will
undoubtedly require HME manufacturing processes. These
are required to be commercialised and perhaps may lead to
new areas of collaboration across pharmaceutical, medical
device, and biotechnology research.
7. Available Commercial Products
Processed via HME
HME-related patents which have been issued for pharmaceu-
tical systems have steadily increased since the early 1980s. So
far, the USA and Germany hold approximately more than
half (56%) of all issued patents for HME in the market [69].
Despite this increased interest, only a handful of commercial-
ized HME pharmaceutical products are currently marketed.
Several companies have been recognized to specialize in
the use of HME as a drug delivery technology, such as
PharmaForm and SOLIQS (Abbott). Recently, SOLIQS has
developed a proprietary formulation which is known as
Meltrex and redeveloped a protease-inhibitor combination
product, Kaletra. Kaletra is mainly used for the treatment
of human immunodeficiency virus (HIV) infections. The
formulated, melt-extruded product was shown to have
a significant enhancement in the bioavailability of active
substances [70]. Furthermore, HME Kaletra tablets were
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Table 1: Diﬀerent hot-melt extruded films comprising diﬀerent polymeric materials, plasticisers, and active ingredients for various indica-
tions.
Film Main polymer(s) Plasticiser/additive Main active ingredient(s) References
1
Acrylic Triacetin
Lidocaine Mididoddi and Repka [68]
Eudragit Triethylcitrate
2
Hydroxypropylcellulose
N/A Ketoconazole Prodduturi et al. [60]
Polyethylene oxide
3
Hydroxypropylcellulose
Polyethylene glycol 3350 Lidocaine Repka et al. [61]Hydroxypropylmethylcellulose
Polyethylene oxide
4 Hydroxypropylcellulose Polyethylene glycol 400 Hydrocortisone Repka et al. [64]
5
Hydroxypropylcellulose
Polyethylene glycol 3350 Clotrimazole Repka et al. [58]
Polycarbophil
6 Polyethylene oxide N/A Ketoprofen Tumuluri et al. [59]
shown to have significant advantages for patient compliance
(i.e., reduced dosing frequency and improved stability)
compared to the previous soft-gel capsule formulation as
recognized by the FDA decision to fast-track approval.
Additionally, Nurofen (Meltlets lemon) is available on the
market as a fast dissolving tablet prepared by similar melting
based technique [43]. Ibuprofen has been used as active
substance in the Meltlets tablets. Moreover, SOLIQS has also
developed a fast-onset ibuprofen system and a sustained-
release formulation of verapamil (Isoptin SR-E) through a
HME-related technology called “Calendaring” that was the
first directly shaped HME product on the market.
8. Conclusion
HME has proven to be a robust method of producing numer-
ous drug delivery systems and therefore it has been found to
be useful in the pharmaceutical industry enlarging the scope
to include a range of polymers and APIs that can be processed
with or without plasticizers. It has also been documented that
HME is a solvent-free, robust, quick, and economy-favoured
manufacturing process for the production of a large variety
of pharmaceutical dosage forms.
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